Sirnaomics Closed Series C1 Financing of US$25 Million and Expands Clinical Programs of Anti-Fibrosis and Anti-Cancer RNAi Therapeutics
GAITHERSBURG, MD, June 6, 2018— Sirnaomics, Inc. (www.sirnaomics.com), a leading biopharmaceutical company in development of RNAi therapeutics, announces today that it has closed Series C1 financing of US$25 Million (RMB￥160 Million). This round of financing was led by Yuexiu New Industrial Investment, followed by Sangel Biomedical Venture Capital, HuaKong Equity Investment and Qianhai Shenghui Investment. The proceeds will be used to expand the clinical programs of the lead anti-fibrosis and anti-cancer RNAi therapeutics, strengthen the management team to support growth
URL link to full story
https://prn.to/2LtUPnY
Media Contact
Michael Molyneaux, MD MBA
(301) 740-1730